Mesothelioma

... Rosetta Genomics Ltd :: Rosetta Genomics Announces it has Presented Data on Advancements Made in the Company's Lead Assay Development Program for Cancer of Unknown Primary (CUP) Rosetta Genomics Announces it has Presented Data on Advancements Made in the Company's Lead Assay Development Program for Cancer of Unknown Primary (CUP) REHOVOT, Israel and NEW BRUNSWICK, New Jersey, April 20 /PRNewswire/ - Rosetta Genomics, Ltd.

(NASDAQ: ROSG), announced today that it has presented updated results on its lead diagnostic development program for cancer of unknown primary (CUP), at the Annual Meeting of the American Association for Cancer Research (AACR), in Los Angeles, California.

The poster, titled "MicroRNA Signature for Identification of Tumor Origin" presented the expansion of the company's CUP assay to include 15 major cancer types, identifiable through a unique signature of 19 microRNAs with 85% accuracy.

In addition, data was presented regarding Rosetta Genomics' proprietary methods for extraction and profiling of microRNAs.

The poster is available for viewing on the company's web site through the following link: http://www.rosettagenomics.com/_Uploads/UtilsMedia/AACR_April2007.jpg About microRNAs MicroRNAs (miRNAs) are recently discovered, naturally occurring small RNAs that act as protein regulators and have the potential to form the basis for a new class of diagnostics and therapeutics.

Since many diseases are caused by the abnormal activity of proteins, the ability t...

Read more...